The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-Germany defends AstraZeneca pivot as key to speeding vaccinations

Fri, 07th May 2021 09:54

* All adults now free to get AZ shot, on doctor's advice

* Gap between doses can be as little as 4 weeks

* Experts warn on reduced efficacy with shorter gap

* Third wave of pandemic "appears to be broken" - minister
(Recasts to lead on AstraZeneca shift)

By Douglas Busvine and Paul Carrel

BERLIN, May 7 (Reuters) - Health Minister Jens Spahn on
Friday defended another U-turn by Germany on the AstraZeneca
vaccine, saying making it available to all adults who
want it would protect more people against COVID-19 more quickly.

Spahn announced late on Thursday that Germany would make
AstraZeneca available to all adults, subject to consulting a
doctor, and allow people to get a second shot as soon as four
weeks after the first.

The move comes with an eye to the summer holidays and
coincides with the rapid passage of legislation that would free
those fully vaccinated from social distancing measures imposed
to fight the pandemic.

Germany had previously limited the shot from the
Anglo-Swedish drugmaker to people over 60 after post-vaccination
monitoring found rare - and sometimes fatal - cases of blood
clotting, with younger women disproportionately affected.

Before that, its vaccine oversight body had said the shot
could not be given to the elderly because of a lack of data from
clinical trials.

With 70% of older people now inoculated and Germany's
vaccination drive gaining momentum, Spahn said the latest step
on AstraZeneca would offer a vaccination option to people who
would otherwise have to wait.

"We are convinced this offer is attractive for those who
would otherwise not get vaccinated so quickly," Spahn told a
news conference, adding that 1 million AstraZeneca doses would
be sent to doctors' practices next week.

THE SOONER, THE WORSE?

The decision by the federal government follows moves by
several German states to make AstraZeneca more widely available
and comes as the pace of giving shots of mainstay vaccines from
BioNTech/Pfizer and Moderna picks up.

The share of the population that has received a first
vaccine shot has reached 31.5%, with 900,000 getting a dose on
Thursday, putting Germany "in the fast lane" by international
standards, said Spahn.

He said the third wave of the coronavirus pandemic "appears
to be broken" while Germany's top public health official, Lothar
Wieler, said infections were falling across all age groups
thanks to social distancing and the progress on vaccinations.

Confirmed cases rose by 18,485 on Friday, with 284
fatalities, while the seven-day incidence fell to 125.7 cases
per 100,000 people, data from the Robert Koch Institute showed.

However, experts criticised the decision to allow people to
receive the AstraZeneca vaccine at shorter intervals, saying
studies had shown its efficacy to be only around 55% with a
four-week gap and 80% with a 12-week delay to the second shot.

"We have to make it clear that if people shorten the gap
between AstraZeneca doses to enjoy greater freedom of movement
sooner, they are doing so at the cost of their immune
protection," said Carsten Watzl, professor of immunology at the
Dortmund Technical University.

Spahn said this was a decision that people should take with
proper advice, a view seconded by Robert Koch Institute head
Wieler.

"We know that the longer the gap before the second shot the
better the protection," Wieler said. "This is an informed
decision people can take in consultation with their doctors."
(Writing by Douglas Busvine
Editing by Gareth Jones)

More News
25 Apr 2024 09:18

TOP NEWS: AstraZeneca upbeat as cancer drugs underpin sales growth

(Alliance News) - AstraZeneca PLC on Thursday hailed the potential of its drugs pipeline as it delivered impressive growth in sales and profit in the first quarter.

Read more
25 Apr 2024 09:12

LONDON MARKET OPEN: Anglo American jumps on takeover bid from BHP

(Alliance News) - Stock prices in London opened mixed on Thursday, as investors cautiously eye data on the health of the US economy.

Read more
25 Apr 2024 08:38

AstraZeneca blows past analysts' estimates for Q1

(Sharecast News) - AstraZeneca posted better-than-expected revenues and profit for the first quarter of 2024 with both the company and analysts highlighting its drug pipeline.

Read more
25 Apr 2024 07:56

REPEAT: Miner Anglo American reviews takeover bid from rival BHP

(Alliance News) - Stocks in London are called to open slightly higher, after a busy start to the day, with corporate earnings and updates.

Read more
25 Apr 2024 07:52

Sanofi profit slips on generic competition and currency effects

April 25 (Reuters) - Sanofi's first-quarter operating income fell 14.7% as currency effects and cheap competition to its multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent, the French drugmaker said on Thursday.

Read more
25 Apr 2024 07:43

LONDON BRIEFING: Miner Anglo American eyes rival BHP takeover

(Alliance News) - Stocks in London are called to open slightly higher, after a busy start to the day, with corporate earnings and updates.

Read more
25 Apr 2024 06:30

Sanofi Q1 profit slips on generic competition, forex effects

April 25 (Reuters) - Sanofi's said on Thursday first-quarter operating income declined 14.7% as unfavourable currency effects and cheap competition to multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent.

Read more
24 Apr 2024 10:32

Angle shares jump on supplier agreement with with AstraZeneca

(Alliance News) - Angle PLC shares rose on Wednesday, after it signed a contract with AstraZeneca PLC.

Read more
24 Apr 2024 10:10

AIM WINNERS & LOSERS: Filtronic jumps as lifts outlook

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
18 Apr 2024 14:17

UK earnings, trading statements calendar - next 7 days

Friday 19 April 
888 Holdings PLCTrading Statement
Man Group PLCTrading Statement
Monday 22 April 
Brave Bison Group PLCFull Year Results
Elixirr International PLCFull Year Results
Frenkel Topping Group PLCFull Year Results
Mobico Group PLCFull Year Results
South32 LtdQ3 Results
Ten Lifestyle Group PLCHalf Year Results
Tuesday 23 April 
Alliance Pharma PLCFull Year Results
Alphawave IP Group PLCFull Year Results
Anglo American PLCTrading Statement
ASA International Group PLCFull Year Results
Associated British Foods PLCHalf Year Results
Eleco PLCFull Year Results
GB Group PLCTrading Statement
Jupiter Fund Management PLCTrading Statement
Maintel Holdings PLCFull Year Results
Property Franchise Group PLCFull Year Results
Taylor Wimpey PLCTrading Statement
tinyBuild IncFull Year Results
Trellus Health PLCFull Year Results
Wednesday 24 April 
1Spatial PLCFull Year Results
abrdn PLCTrading Statement
Ecora Resources PLCTrading Statement
Fresnillo PLCTrading Statement
Lloyds Banking Group PLCQ1 Results
Nichols PLCTrading Statement
PensionBee Group PLCFirst Quarter Results
PZ Cussons PLCTrading Statement
Reckitt Benckiser Group PLCTrading Statement
Sanderson Design Group PLCFull Year Results
Serica Energy PLCFull Year Results
Star Energy Group PLCFull Year Results
Tortilla Mexican Grill PLCFull Year Results
Tracsis PLCHalf Year Results
Warpaint London PLCFull Year Results
Thursday 25 April 
Aquila European Renewables PLCFull Year Results
Argo Blockchain PLCFull Year Results
AstraZeneca PLCQ1 Results
Barclays PLCQ1 Results
Checkit PLCFull Year Results
Coca-Cola Europacific Partners PLCTrading Statement
Destiny Pharma PLCFull Year Results
Hikma Pharmaceuticals PLCTrading Statement
Focusrite PLCHalf Year Results
Ibstock PLCTrading Statement
Inchcape PLCTrading Statement
J Sainsbury PLCFull Year Results
London Stock Exchange Group PLCQ1 Results
Persimmon PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
PureTech Health PLCFull Year Results
Relx PLCTrading Statement
Renewi PLCTrading Statement
Schroders PLCQ1 Results
Skillcast Group PLCFull Year Results
Travis Perkins PLCTrading Statement
Trifast PLCTrading Statement
Unilever PLCQ1 Results
WAG Payment Solutions PLCTrading Statement
Weir Group PLCTrading Statement
WH Smith PLCHalf Year Results
WPP PLCTrading Statement
Zinc Media Group PLCFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
16 Apr 2024 09:48

LONDON BROKER RATINGS: RBC raises Admiral; Barclays cuts Phoenix Group

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
16 Apr 2024 09:30

Boehringer replaces Bayer as Germany's largest drugmaker on Jardiance gains

INGELHEIM, Germany, April 16 (Reuters) - Boehringer Ingelheim on Tuesday overtook Bayer as Germany's largest drugmaker when the unlisted company reported a currency-adjusted gain in 2023 pharmaceutical sales of 10.3% to 20.8 billion euros ($22.11 billion).

Read more
16 Apr 2024 08:39

AstraZeneca's hails Imfinzi survival data on cancer form

(Alliance News) - AstraZeneca PLC on Tuesday said that its immunotherapy Imfinzi showed positive survival rate in people with advanced biliary tract cancer.

Read more
12 Apr 2024 12:55

EU regulator rules out link between weight-loss drugs and suicidal thoughts

April 12 (Reuters) - The European Union drug regulator found no evidence that a class of diabetes and weight-loss drugs such as Novo Nordisk's hugely popular Wegovy, are linked to suicidal thoughts, it said on Friday, ending a nine-month probe.

Read more
11 Apr 2024 18:51

AstraZeneca CEO could earn 19 million pounds as pay measure clears opposition

Policy approved with two-third of votes in favour

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.